Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus THEOCLEAR 100.
FORADIL vs THEOCLEAR-100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
Bronchodilator
Bronchodilator